Evidence map›Paper›PMID 42094891›Full record

ArticleFrontiers in public health2026

Effectiveness of disease management across healthcare settings: the Multiple Sclerosis Center is a pillar for multi-disciplinary practices that promote quality of life for people with Multiple Sclerosis.

Eleni Grigoriadou, Eleni Polyzoidou, Christos Bakirtzis, Charis Mylonas, Evangelia Kesidou, Theano Tatsi, Elli Nteli, Natalia Konstantinidou, Charis Styliadis, Aliki Vrienniou and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eleni Grigoriadou2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.
Eleni Polyzoidou2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.
Christos Bakirtzis2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.
Charis Mylonas2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.
Evangelia Kesidou2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.
Theano Tatsi2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.
Elli Nteli2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.
Natalia Konstantinidou2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.
Charis StyliadisLaboratory of Medical Physics and Digital Innovation, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece.
Aliki VrienniouHellenic Federation of Persons with Multiple Sclerosis (HFoPwMS), Athens, Greece.
Georgios PapazisisDepartment of Clinical Pharmacology, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece.
Panagiotis BamidisLaboratory of Medical Physics and Digital Innovation, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece.
Marina Kleopatra Boziki2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.
Nikolaos C Grigoriadis2nd Neurological University Department, Multiple Sclerosis Center, Aristotle University of Thessaloniki, AHEPA General Hospital of Thessaloniki, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Multiple Sclerosis (MS) is a chronic neurological disorder, prevalent in young adults. MS leads in disability accrual, thus affecting overall patients' quality of life. Moreover, the management of MS poses significant burden on health systems worldwide. The present study delves into the impact of different health providing settings (e.g. private office/Clinic vs. specialized MS Center) on the effectiveness of MS management, as well as on patient-reported outcomes related to the quality of life (Axis A). Moreover, the study addresses their relative effectiveness in a health crisis, such as the COVID-19 pandemic (Axis B). Methods: Data were collected based on questionnaires administered to people with MS (pwMS). Upon the pandemic and prior to the COVID-19 vaccines being available, all data were collected via online questionnaires. Since March 2021, data were collected both online and in person. Results: Overall, 776 pwMS participated in the study and answered Axis B questionnaire. Of those, 215 additionally answered Axis A questionnaire. Regarding Axis A, disease management by a specialized MS Center was associated with increased access to healthcare professionals (p < 0.001) and/or MRI examinations ( Discussion: These findings suggest that care delivered in specialized MS centers is associated with improved access to healthcare services and better patient-reported outcomes, both under routine care conditions and during healthcare crises.

Indexed as

Disease ManagementMultiple SclerosisQuality of LifeAdultCOVID-19FemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresSurveys and Questionnairesmultidisciplinary health servicesMultiple SclerosisMultiple Sclerosis Centerpersonalized carequality of life

Identifiers

PMID42094891
PMCPMC13142094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.